Diabetic Retinopathy VA Rating

Diabetic retinopathy is one of the cleaner secondary claims in the VA system, and that is exactly why so many of them go sideways. When diabetes is already service-connected, the link from diabetes to the retinopathy is usually straightforward, because the eye disease is a recognized complication of diabetes. Under 38 CFR § 3.310 (opens in a new tab), a disability that is proximately due to or the result of a service-connected condition is service connected too. So the question that decides most of these claims is not whether the condition is connected. It is how much the disease affects your vision, how often it needs treatment, and whether the C&P exam actually measured both.

That is where the file falls apart. Diabetic retinopathy is rated under the General Rating Formula for Diseases of the Eye in 38 CFR § 4.79 (opens in a new tab). The formula gives two paths: visual impairment, meaning visual acuity and visual field measured together, or incapacitating episodes counted as treatment visits over the past 12 months, whichever produces the higher rating. If the exam records corrected acuity and skips the visual field testing, or never counts the injection visits, the rating is built on half the picture. Remand is the most common Board outcome on this condition, and an incomplete exam is exactly the kind of gap a remand exists to fix.

This page covers the rating criteria, what each level pays, how acuity and field combine into a number, the treatment-visit path that reaches 60 percent, the secondary link to diabetes, what the C&P examiner has to measure, and why VA denies these claims.

TL;DR

• Diabetic retinopathy is rated under 38 CFR § 4.79 through the General Rating Formula for Diseases of the Eye. The schedule has listed it by name as DC 6040 since May 13, 2018, and many rating decisions still use DC 6006 (retinopathy or maculopathy not otherwise specified). Both codes use the same formula.
• The formula rates either visual impairment, scored from visual acuity (the eye chart) and visual field (peripheral vision, by Goldmann or automated perimetry), or incapacitating episodes, whichever produces the higher rating.
• The old "minimum 10% during active pathology" rule is gone. It left the eye schedule in the revision effective December 10, 2008, and the current § 4.79, rewritten effective May 13, 2018, uses something considerably better: an incapacitating-episodes ladder counted in treatment visits, reaching 60% at 7 or more visits in 12 months.
• Anti-VEGF injections count as treatment visits. Note (2) to the formula names intravitreal and periocular injections and laser treatments as examples of treatment, and Note (1) defines an incapacitating episode as an eye condition severe enough to require a clinic visit specifically for treatment. A veteran on a monthly injection schedule has 12 qualifying visits a year.
• This is almost always a secondary condition to service-connected diabetes mellitus under 38 CFR § 3.310. When diabetes is service-connected, the nexus is usually straightforward and the dispute is over severity.
• The clinical markers that drive severity are proliferative diabetic retinopathy, macular edema, and treatment history: laser photocoagulation, anti-VEGF injections, and vitrectomy.
• A compensable retinopathy rating is assigned separately from the diabetes rating. Under DC 7913 Note (1), only noncompensable complications, or complications used to support a 100 percent diabetes rating, are folded into the diabetes percentage.
• Acuity is rated on corrected distance vision (with glasses), not uncorrected, with limited exceptions.
• Across 1,349 decided Board rulings on diabetic retinopathy from 2021 to 2026, 24.0% were granted, 32.2% denied and 43.8% remanded. A ruling is one issue the Board decided in one decision; one decision often rules on several issues.

Diabetic retinopathy VA rating criteria (DC 6040 and DC 6006)

Since the eye rule that took effect May 13, 2018 (83 FR 15316), the schedule in 38 CFR § 4.79 (opens in a new tab) lists diabetic retinopathy by name as DC 6040. Many rating decisions, and many Board decisions, still cite DC 6006, retinopathy or maculopathy not otherwise specified. Neither code carries its own table of percentages. Both send the rating to the General Rating Formula for Diseases of the Eye, which gives you two paths and directs VA to take whichever pays more. The incapacitating-episodes path counts treatment visits over a 12-month period, and for diabetic retinopathy under active management it is frequently the higher-paying path. The formula reads as follows.

Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation

With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months, 60%

With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months, 40%

With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months, 20%

With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months, 10%

Two notes define the terms. Note (1) says an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes. Note (2) gives examples of qualifying treatment, and they include intravitreal or periocular injections and laser treatments.

Read those together and the practical consequence is large. "Incapacitating episode" sounds like it should mean bed rest or hospitalization. It does not. It means a treatment visit. A veteran on a monthly anti-VEGF injection schedule for macular edema has twelve qualifying visits in twelve months, which is comfortably past the seven-visit threshold for 60 percent, and that evaluation is available even if corrected acuity is 20/40 and the visual field is full.

If you have read that active retinopathy carries a "minimum 10 percent," that rule is gone. It belonged to the eye schedule in force before December 10, 2008. The version used from then until May 13, 2018 counted incapacitating episodes in weeks of prescribed bed rest, and the current formula counts treatment visits instead. Active disease under ongoing treatment is now compensable regardless of acuity, with a 60 percent ceiling on that path rather than a 10 percent floor. Older Board decisions in any dataset describe those earlier criteria.

The practical instruction follows directly. Count and date the visits. An injection log, a procedure record, or a printout of ophthalmology encounters over the past twelve months is the single highest-value document on this claim, and it is one most veterans never think to submit because nothing in the process asks for it.

How much VA pays for diabetic retinopathy

For a single veteran with no dependents at the 2026 rates (effective December 1, 2025), the treatment-visit levels pay as follows.

• 10% pays $180.42 a month.
• 20% pays $356.66 a month.
• 40% pays $795.84 a month.
• 60% pays $1,435.02 a month.

The visual-impairment path can go higher when vision loss in both eyes is severe; 20/200 in both eyes, for example, rates 70 percent. VA pays by your combined rating, so the retinopathy rating adds money only when it changes the combined percentage.

How visual acuity and visual field set the rating

Visual impairment under § 4.75 is based on visual acuity, visual field and muscle function, and for retinopathy the first two matter most. When both decreased acuity and a field defect are present and service connected, § 4.77(c) has VA evaluate each separately, expressing the field defect as a level of visual acuity, and combine the two evaluations under § 4.25.

Visual acuity. Acuity is rated on corrected distance vision under § 4.76(b), meaning with your glasses or contacts on, with narrow exceptions. The acuity table in § 4.79 pairs the two eyes. 20/40 in each eye rates 0 percent, 20/50 in one eye with 20/40 in the other rates 10 percent, 20/100 in both eyes rates 50 percent, and the scale reaches 100 percent for severe loss in both eyes. If only one eye is service connected, VA treats the other eye as 20/40 (with an exception in § 3.383 for serious loss in both eyes), and one eye alone cannot rate above 30 percent for visual impairment unless the eye is lost. Diabetic macular edema is the classic driver of central acuity loss, because the swelling sits in the macula, the part of the retina responsible for sharp central vision.

Visual field. Field is the other half. Proliferative retinopathy, vitreous hemorrhage and panretinal laser can all reduce the peripheral field even when the eye chart reads well; in a large randomized trial, eyes treated with panretinal laser lost more peripheral field than eyes treated with ranibizumab injections (PMID 26565927). Under § 4.77(a), field loss must be measured by Goldmann kinetic perimetry or an automated perimeter with simulated kinetic Goldmann testing, with results for at least 16 meridians in each eye. VA averages the remaining field across eight principal meridians and converts it to a rating: a remaining field of 16 to 30 degrees, for example, rates 50 percent in both eyes or 10 percent in one. That is why a veteran with decent acuity but heavily treated proliferative disease can still rate higher than the acuity table alone would suggest, but only if someone actually ran the perimetry.

The practical takeaway is that a rating built on acuity alone is incomplete when the disease affects the field. Section 4.75(b) allows field testing when there is a medical indication of a disease that may cause a field defect, and treated proliferative retinopathy is one.

Diabetic retinopathy secondary to diabetes

Diabetic retinopathy is, by definition, a complication of diabetes: chronic high blood sugar damages the small blood vessels of the retina (PMID 36815723). Under 38 CFR § 3.310 (opens in a new tab), a condition caused by a service-connected disability is service connected as a secondary condition. A condition aggravated by a service-connected disability, meaning it would be less severe but for that disability, is service connected for the added severity (Allen v. Brown, 7 Vet. App. 439 (1995)).

When diabetes is already service-connected, the nexus for the retinopathy is usually the easy part. An ophthalmology or optometry record that diagnoses diabetic retinopathy in a veteran with established diabetes generally carries the connection. The nexus opinion does not have to do heavy lifting here the way it does in a knee-to-back gait-compensation theory. The diagnosis itself names the cause. If your diabetes is service connected through herbicide exposure, type 2 diabetes is on the Agent Orange list in 38 CFR § 3.309(e), and the retinopathy follows it as a secondary condition.

Diabetic retinopathy claimed secondary to diabetes is one of the publishable pairs in the Board data, and the Board section below lists it with its count and grant rate. In the Board's 2021 to 2026 service connection rulings, secondary claims were granted far more often than direct ones; the Board section below shows both rates.

That is exactly why the contested issue migrates to severity. VA grants the connection, assigns an acuity-based number or a visit-count number, and the real dispute becomes whether the exam captured the full extent of the vision loss and the treatment history. A compensable retinopathy rating is separate from the diabetes percentage, so it is combined with the diabetes rating under § 4.25 rather than absorbed into it. DC 7913 Note (1) folds in only noncompensable complications, or complications used to support a 100 percent diabetes rating.

The same diabetic logic opens other secondaries off the same root disease: peripheral neuropathy in the extremities, kidney disease, and cardiovascular conditions. Secondary conditions to diabetes lists those chains with their Board results, and the secondary conditions tool helps map them to your record.

The diabetic retinopathy C&P eye exam

The eye C&P exam follows the DBQ for eye conditions, and the rating is only as good as the measurements in it. Under § 4.75(b), the examiner must be a licensed optometrist or ophthalmologist, and the fundus must be examined with your pupils dilated unless that is medically unsafe. For diabetic retinopathy, the report should record these items.

• Best-corrected distance acuity in each eye, with the correction noted, not just uncorrected vision.
• Visual field testing by Goldmann kinetic perimetry or automated (for example Humphrey) perimetry, with the plotted results, in each eye.
• Staging of the retinopathy: nonproliferative versus proliferative, and presence or absence of macular edema.
• Treatment history with dates and a total count: laser photocoagulation, anti-VEGF injections, vitrectomy. The number of treatment visits in the past 12 months is a rating criterion in its own right, so the count matters as much as the fact of treatment.

Why staging and treatment matter. Proliferative diabetic retinopathy, where abnormal new blood vessels grow on the retina, is the most serious stage and can lead to vitreous hemorrhage, tractional retinal detachment and loss of both central and peripheral vision (PMID 36815723). Diabetic macular edema can arise at any stage and is the main cause of vision impairment in people with diabetes, and anti-VEGF injections are the first-line treatment for it (PMIDs 20186318 and 36359761). Laser, injections and vitrectomy are each evidence of severity, and each treatment visit counts toward the ladder.

A file that records "diabetic retinopathy, stable" without staging, without acuity and field numbers, and without a dated treatment-visit count gives the rater almost nothing to work with. A file that documents proliferative disease, recurrent macular edema, a history of panretinal laser, and a year of anti-VEGF injections tells a severity story the rating tables can actually price. When the exam is complete, the rater can run both paths and take whichever is higher, which is what the formula directs. When it is sparse, the rater defaults downward.

Why VA denies diabetic retinopathy claims

Across 1,349 decided Board rulings on diabetic retinopathy from 2021 to 2026, 24.0% were granted, 32.2% denied and 43.8% remanded. The grant rate is about level with the 24.7 percent across all decided Board rulings, and remand is the most common outcome. When the Board denied service connection, it most often found no link between the retinopathy and service; the Board section below shows how often each part of the claim failed, why claims were sent back, and how service connection appeals compared with appeals for a higher rating. In the decisions I read, the same gaps repeat.

Visual field never tested. This is the central gap. The exam records corrected acuity and stops. Because the rating is supposed to combine the acuity-based and field-based evaluations, an exam with no perimetry can only produce an acuity number. A veteran with extensive panretinal laser and contracted peripheral fields gets rated as if the field loss did not exist. Appeals for a higher rating, where this gap does its damage, were granted less often than service connection appeals.

Severity frozen at one snapshot. Diabetic retinopathy progresses. An exam from three years ago that found mild nonproliferative disease does not describe a veteran who has since developed macular edema and started anti-VEGF injections. When the file is not updated, the rating lags the disease, and the Board sends such cases back for a current exam.

No staging or treatment timeline. A note that says "diabetic retinopathy" without distinguishing nonproliferative from proliferative, without noting macular edema, and without the laser and injection dates leaves the rater unable to price severity. The visit count that could have carried the claim to 40 or 60 percent is never assembled.

The treatment-visit path never run. Some decisions rate a veteran with stable corrected acuity at zero, never counting the ongoing anti-VEGF injections or repeat laser treatments that the General Rating Formula treats as incapacitating episodes. The formula requires evaluating both paths and taking the higher, and seven qualifying visits in twelve months reaches 60 percent.

Best-corrected versus uncorrected confusion. Acuity is rated on corrected distance vision with limited exceptions. A record that only captures uncorrected acuity, or mixes the two, muddies the rating input and invites a number that does not survive review.

No service-connected diabetes behind a direct claim. Retinopathy filed as a direct claim needs in-service onset and a nexus, which is rarely available for a disease that follows years of diabetes. The claim works when it is tied to service-connected diabetes.

Questions veterans ask about diabetic retinopathy

What is the VA rating for diabetic retinopathy?

VA rates diabetic retinopathy on treatment visits in the past 12 months or on vision loss, whichever is higher. One or two treatment visits rate 10 percent, three or four rate 20 percent, five or six rate 40 percent, and seven or more rate 60 percent, while severe vision loss in both eyes can rate up to 100 percent.

Do eye injections count as treatment visits for a VA rating?

Yes. Note (2) to the General Rating Formula lists intravitreal or periocular injections and laser treatments as examples of treatment, and each clinic visit specifically for treatment counts. A monthly anti-VEGF schedule gives you 12 visits a year, past the 7 needed for 60 percent.

Is diabetic retinopathy rated separately from diabetes?

Yes, once it is compensable. Under DC 7913 Note (1), VA rates compensable complications of diabetes separately unless they support a 100 percent diabetes rating, and only noncompensable complications stay inside the diabetes percentage.

Can I get a VA rating for diabetic retinopathy in one eye?

Yes. If only one eye is service connected, VA treats the other eye as 20/40, and the visual impairment rating for one eye cannot exceed 30 percent unless the eye is lost. That cap is written for visual impairment, so ask VA to rate the treatment-visit path too if you get regular injections in that eye.

Is diabetic retinopathy an Agent Orange presumptive condition?

Not by itself. Type 2 diabetes is on the herbicide list in 38 CFR § 3.309(e), and retinopathy caused by service-connected diabetes is then service connected as a secondary condition under § 3.310.

Bottom Line

Diabetic retinopathy ratings turn on a paradox. The hard part of most claims, the nexus, is usually easy here because the disease is a recognized complication of service-connected diabetes under § 3.310. The easy-sounding part, the rating number, is where these claims actually live or die, because the General Rating Formula for Diseases of the Eye demands two measurements, acuity and visual field, taken together, or a count of treatment visits over the past 12 months, whichever produces the higher rating. The cases that come out right have a complete eye exam: best-corrected acuity in each eye, real perimetry, clear staging of nonproliferative versus proliferative disease and macular edema, and a dated treatment history of laser, anti-VEGF injections, and any vitrectomy. The cases that get remanded, which is the most common outcome in the dataset, tend to be the ones where the field testing never happened or the exam captured a snapshot the disease had already outgrown. Same eye, different paper trail, different rating.

Related Conditions

Diabetic retinopathy connects most directly to diabetes, the service-connected root that makes the secondary nexus straightforward. It shares the § 4.79 visual-impairment rating mechanics with other eye conditions, including cataracts (which people with type 2 diabetes develop more often, PMID 25060855), glaucoma, and dry eye. Veterans working a diabetic retinopathy claim should also look at the broader set of diabetic complications, including peripheral neuropathy and kidney disease, and use the secondary conditions tool to map the full chain off diabetes before assuming one eye rating tells the whole story.

Methodology and Limitations

• Data source: Rating criteria quoted from 38 CFR § 4.79, the General Rating Formula for Diseases of the Eye (DC 6040 and DC 6006), with visual-impairment evaluation under §§ 4.75, 4.76, 4.76a and 4.77, checked against the eCFR text in October 2026. The current eye criteria took effect May 13, 2018 (83 FR 15316). Secondary service connection from § 3.310 and Allen v. Brown, 7 Vet. App. 439 (1995). DC 7913 Note (1) from § 4.119. Combined ratings math from § 4.25. Medical background from PubMed abstracts (PMIDs 36815723, 20186318, 36359761, 26565927 and 25060855).
• Board snapshot: Across 1,349 decided Board rulings on diabetic retinopathy from 2021 to 2026, 24.0% were granted (including partial grants and mixed outcomes), 32.2% denied and 43.8% remanded. Another 117 dismissed or withdrawn rulings are excluded. These are appealed claims, not your personal odds.
• Sample size: Patterns in this post are drawn from Claim Raven's read of 511,036 Board decisions from 2021 to 2026, which contain 1,378,030 rulings, including 1,466 rulings on diabetic retinopathy. The Board section on this page breaks these down by denial reason, remand reason, appeal type, medical opinion, claim theory, era and secondary pair; those figures are computed from the data, not typed here. The data does not break results down by measurement (acuity versus field).
• Classification approach: Diagnostic code and rating-formula definitions drawn from the regulatory text. Severity markers (proliferative retinopathy, macular edema, laser photocoagulation, anti-VEGF injections, vitrectomy) reflect the clinical staging that the visual-impairment and treatment-visit criteria depend on. Secondary-connection analysis follows § 3.310.
• Limitations:
• Compensation depends on best-corrected acuity and visual field measurements that must come from a complete eye exam. Without both, the rating is built on partial evidence.
• The current formula has no active-disease minimum. The incapacitating-episodes path counts documented treatment visits, and whether a given clinic visit was specifically for treatment can be contested.
• Diabetic retinopathy progresses over time, so a rating reflects the exam date, not necessarily current severity.
• Selection bias: BVA-level patterns reflect cases that appealed. Most diabetic retinopathy claims resolve at the RO level and are not in any BVA dataset.
• Application of the visual-field evaluation rules at the RO level is uneven, which is part of why missing field testing is a recurring gap.
• These observations reflect patterns from the regulatory text and BVA decisions. They are not predictions of individual outcomes.